MIBAVA-Mechanistic Interrogation of Bicuspid Aortic Valve associated Aortopathy
Description: Bicuspid aortic valve (BAV), a condition in which there are two valve leaflets instead of the normal three, is the most common congenital cardiac malformation, affecting from 1% to 2% of the population. It appears to be highly heritable, is more common in males than females, and is frequently associated with other aortic pathology, such as ascending aortic aneurysm. The goal of the MIBAVA network is to identify factors that affect the clinical outcome of patients with BAV, with particular attention to the progression of aortic aneurysm. The scope of the research program will span natural history and epidemiologic studies, exploration and application of advanced imaging techniques, use of advanced genetic methods to identify disease-related genes and pathways, basic science investigations to identify predisposing mechanisms at the biochemical, cellular and tissue level, and the complementary use of various model systems. With progress in understanding the etiology of aneurysm formation, the network will turn to the search for novel therapeutic strategies and the development of individualized treatment protocols.
Funder: Fondation Leducq
Funding type: research
Funder scheme: Transatlantic Networks of Excellence
Start date: 2012-01-01
Investigators: Bart Loeys, Harry Dietz, Bart Loeys, Harry Dietz, Lut van Laer, Andy McMALLION, Per Eriksson, Luc Mertens, Salah A. Mohamed, Gregor Andelfinger
Institutions: University of Antwerp, Johns Hopkins University, Baltimore, Anders FRANCO-CERECEDA, Karolinska Institute, Stockholm, SEEMA MITTAL, Sickkids University Hospital, Toronto, Lübeck University Hospital, Sainte-Justine Hospital, Montréal
Funded outputs count: 26
Funder award ID: 12CVD03
OpenAlex ID: G8042276178